Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15029 | 666 | 45.4 | 66% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CONDITIONED PLACE PREFERENCE | Author keyword | 24 | 13% | 26% | 172 |
2 | PLACE CONDITIONING | Author keyword | 8 | 19% | 6% | 37 |
3 | INTRACRANIAL SELF ADMINISTRATION | Author keyword | 5 | 29% | 2% | 14 |
4 | PLACE APPROACH | Author keyword | 3 | 100% | 0% | 3 |
5 | PLACE PREFERENCE | Author keyword | 3 | 12% | 3% | 22 |
6 | CONDITIONED PLACE PREFERENCE CPP | Author keyword | 2 | 19% | 2% | 11 |
7 | CONDITIONED PLACE AVERSIONS | Author keyword | 2 | 67% | 0% | 2 |
8 | CONDITIONED PLACE PREFERENCE AVERSION | Author keyword | 2 | 67% | 0% | 2 |
9 | MECHANISMS DRUG ACT GRP | Address | 2 | 67% | 0% | 2 |
10 | DOPAMINE RECEPTOR SUPERSENSITIVITY | Author keyword | 2 | 25% | 1% | 6 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEROIN REWARD | 13 | 49% | 3% | 19 |
2 | CNS SITES | 9 | 59% | 2% | 10 |
3 | REINFORCING PROPERTIES | 4 | 13% | 4% | 26 |
4 | MEASURING REWARD | 4 | 21% | 2% | 15 |
5 | OPIATE REWARD | 3 | 32% | 1% | 9 |
6 | MOTIVATIONAL PROPERTIES | 3 | 15% | 3% | 22 |
7 | DRUG REINFORCEMENT | 3 | 22% | 2% | 13 |
8 | DRUG APPLICATION | 2 | 67% | 0% | 2 |
9 | GINSENG TOTAL SAPONIN | 2 | 33% | 1% | 5 |
10 | COCAINE INDUCED HYPERACTIVITY | 2 | 36% | 1% | 4 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
CONDITIONED PLACE PREFERENCE USING OPIATE AND STIMULANT-DRUGS - A METAANALYSIS | 1995 | 258 | 78 | 69% |
Conditioned place preference: what does it add to our preclinical understanding of drug reward? | 2000 | 538 | 117 | 33% |
What's conditioned in conditioned place preference? | 2013 | 30 | 46 | 26% |
Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues | 1998 | 717 | 581 | 31% |
Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies | 1999 | 353 | 113 | 30% |
Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade | 2007 | 479 | 960 | 14% |
Neurobiological mechanisms of the reinstatement of drug-conditioned place preference | 2009 | 87 | 120 | 19% |
TRENDS IN PLACE PREFERENCE CONDITIONING WITH A CROSS-INDEXED BIBLIOGRAPHY, 1957-1991 | 1993 | 145 | 193 | 51% |
Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens | 1998 | 271 | 203 | 33% |
LOCALIZATION OF DRUG REWARD MECHANISMS BY INTRACRANIAL INJECTIONS | 1992 | 196 | 99 | 24% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MECHANISMS DRUG ACT GRP | 2 | 67% | 0.3% | 2 |
2 | ADDICT OUTPATIENT CLIN | 1 | 50% | 0.2% | 1 |
3 | DRUG IDR | 1 | 50% | 0.2% | 1 |
4 | INSERM U 266 | 1 | 50% | 0.2% | 1 |
5 | NUCL BIOPHYS | 1 | 50% | 0.2% | 1 |
6 | SUBSTANCE ABUSE DEPENDENCE | 1 | 50% | 0.2% | 1 |
7 | UMR7157U705 | 1 | 50% | 0.2% | 1 |
8 | UNITE NEUROSCI COMPORTEMENTALES PSYCHOPHARMACOL | 1 | 50% | 0.2% | 1 |
9 | CNRS UMR 5807 | 1 | 25% | 0.3% | 2 |
10 | PSYCHIAT BEHAV SCI R629 | 0 | 20% | 0.3% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000259805 | BRAIN STIMULATION REWARD//SELF STIMULATION//INTRACRANIAL SELF STIMULATION |
2 | 0.0000217148 | REINSTATEMENT//SELF ADMINISTRATION//BEHAV NEUROSCI BRANCH |
3 | 0.0000176859 | MORPHINE WITHDRAWAL//EQUIP CELLULAR MOL PHARMACOL//ACUTE DEPENDENCE |
4 | 0.0000172079 | BEHAVIORAL SENSITIZATION//BEHAV PHARMACOL GRP//CONDITIONED DRUG EFFECTS |
5 | 0.0000166372 | VENTRAL PALLIDUM//STRIATOPALLIDUM//ORAL CRANIOMAXILLO IAL RE IYODA KU |
6 | 0.0000159031 | SALVINORIN A//SALVIA DIVINORUM//KAPPA OPIOID RECEPTOR |
7 | 0.0000149755 | BACLOFEN//CGP44532//POSTSYNAPTIC DOPAMINE RECEPTOR SUPERSENSITIVITY |
8 | 0.0000138418 | ANERGIA//OPERANT//DOLE 4011 |
9 | 0.0000133186 | PSYCHONEUROPHARMACOL//NORADRENALINE DOPAMINE INTERACTIONS//NOREPINEPHRINE DOPAMINE INTERACTIONS |
10 | 0.0000118202 | LEWIS//F344//LEW |